- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01028079
Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain
December 8, 2009 updated by: Bayer
Placebo and Active Controlled, Double Dummy Phase III Study to Prove Efficacy of Aspirin (1000 mg Solid Dose) in Treatment of Acute Low Back Pain.
The purpose of this study is to determine the efficacy and safety of 1000 mg Aspirin (the study medication) by comparing it to placebo (the control group without active substance) or 400 mg Ibuprofen (the control group with an active substance) in treating the symptoms of back pain.
The study is designed to develop a treatment method against back pain which will have more advantages for patients than the methods that are currently available.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
338
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bad Lippspringe, Germany, 33175
-
Beckum, Germany, 59269
-
Einbeck, Germany, 37574
-
Hamburg, Germany, 20148
-
Hamburg, Germany, 20459
-
Hamburg, Germany, 21031
-
Hamburg, Germany, 22177
-
Hannover, Germany, 30519
-
Künzing, Germany, 94550
-
Straßkirchen, Germany, 94342
-
-
-
-
-
Fowey, United Kingdom, PL23 1DT
-
Saltash, United Kingdom, PL12 6DL
-
Sheffield, United Kingdom, S3 9DA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ambulatory male or female, 18 to 70 years of age
- Body mass index ranging in-between 18 and 30 kg/m²
- Normal blood pressure
- Patients suffering from low back pain
- Low back pain, localized below the costal margin and above the inferior gluteal folds, either as acute low back pain, or as chronic or intermittent low back pain
Exclusion Criteria:
- Hypersensitivity to acetylsalicylic, salicylates, or other Non Steroidal Anti-inflammatory drugs
- Serious physical illness especially uncontrolled disorders of kidney, liver, lung, heart or brain function, neurological disorders or severe chronic or terminal disease
- Pregnancy or lactation period
- Abuse of alcohol or addictive substances
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 2
|
Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours).
Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
|
Experimental: Arm 1
|
Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours).
Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
|
Placebo Comparator: Arm 3
|
Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve of the baseline adjusted pain intensity curve over the initial 48 hours (AUC-PI0-48hours) after first dosing
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total pain relief 6, 72, 96 and 120 hours after first dosing
Time Frame: 6, 72, 96 and 120 hours
|
6, 72, 96 and 120 hours
|
Pain intensity relief over initial 6 hours
Time Frame: 6 hours
|
6 hours
|
Pain intensity difference after 48, 72, 96 and 120 hours after first dosing
Time Frame: 48, 72, 96 and 120 hours
|
48, 72, 96 and 120 hours
|
Overall efficacy after 48, 72, 96 and 120 hours after first dosing
Time Frame: 48, 72, 96 and 120 hours
|
48, 72, 96 and 120 hours
|
Total dose used over 5 days
Time Frame: 5 days
|
5 days
|
Time till use of rescue medication
Time Frame: 5 days
|
5 days
|
Safety - assessment of adverse events
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Primary Completion
December 7, 2022
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
December 8, 2009
First Submitted That Met QC Criteria
December 8, 2009
First Posted (Estimate)
December 9, 2009
Study Record Updates
Last Update Posted (Estimate)
December 9, 2009
Last Update Submitted That Met QC Criteria
December 8, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Back Pain
- Low Back Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
- Ibuprofen
Other Study ID Numbers
- 11818
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Palmer College of ChiropracticDepartment of Health and Human ServicesCompletedChronic Low Back Pain | Subacute Low Back PainUnited States
-
Universität Duisburg-EssenSiemens-BetriebskrankenkasseCompletedChronic Low Back Pain | Recurrent Low Back Pain
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Apsen Farmaceutica S.A.CompletedLow Back Pain | Low Back Pain, Mechanical | Acute Low Back PainBrazil
Clinical Trials on Ibuprofen
-
Reckitt Benckiser Healthcare (UK) LimitedPremier Research Group plcCompletedStomatognathic Diseases | Tooth Diseases | Tooth, ImpactedUnited States
-
Reckitt Benckiser Healthcare (UK) LimitedTerminated
-
Reckitt Benckiser Healthcare (UK) LimitedSimbec ResearchCompletedHealthy Volunteer Study
-
Overseas Pharmaceuticals, Ltd.Virginia Contract Research Organization Co., Ltd.Terminated
-
Fundacion para la Investigacion Biomedica del Hospital...CompletedPatent Ductus ArteriosusSpain
-
Darnitsa Pharmaceutical CompanyACDIMA BiocenterCompletedHealthy Subjects | BioequivalenceJordan
-
Pierre Fabre MedicamentCompleted
-
Indonesia UniversityCompleted
-
SocraTec R&D GmbHSocraMetrics GmbHCompleted